

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/656,029	09/05/2003	Michael Allen Whitney	VPI/02-143 US2

CONFIRMATION NO. 8813

FORMALITIES LETTER



OC000000012370026

James J. Wong
 Vertex Pharmaceuticals Incorporated
 130 Waverly Street
 Cambridge, MA 02139-4242

Date Mailed: 04/15/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

08/18/2004 FFAIAI2 00000044 500725 10656029

02 FC:1051

130.00 DA

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$130 for a Large Entity

- \$130 Late oath or declaration Surcharge.

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Our Docket No.: VPI/02-143 US2




Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On August 11, 2004.
Date

1. Fee Transmittal Sheet (1 page, in duplicate);
2. Petition for 2 Month Extension of Time (1 page, in duplicate);
3. Response to NTFMP (2 pages, in duplicate);
4. Copy of Notice to File Missing Part of Nonprovisional Application;
5. Executed Declaration/Power of Attorney document (9 pages);
6. Submission of Paper Copy and CR Copy of Sequence Listing (2 pages, in duplicate);
7. Statement Accompanying Sequence Listing (1 page);
8. Sequence Listing (102 pages);
9. Certificate of Express Mail page; and
10. This Return Postcard Receipt.


Signature

Karen DiRocco
Typed or printed name of person signing Certificate



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2004 <small>Patent fees are subject to annual revision.</small>		Complete if Known	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Application Number	10/656,029
TOTAL AMOUNT OF PAYMENT (\$)		Filing Date	September 5, 2003
550.00		First Named Inventor	Michael Allen Whitney
		Examiner Name	Not Yet Assigned
		Group Art Unit	1636
		Attorney Docket No.	VPI/02-143 US2
METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		3. ADDITIONAL FEES	
<input checked="" type="checkbox"/> Deposit Account		Large Entity Small Entity	
Deposit Account Number 50-0725		Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee Paid	
Deposit Account Name Vertex Pharmaceuticals		1051 130 2051 65 Surcharge - late filing fee or oath 130.00	
The Commissioner is hereby authorized to: (check all that apply)		1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet.	
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments		1053 130 1053 130 Non-English specification	
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application		1812 2,520 1812 2,520 For filing a request for <i>ex parte</i> reexamination	
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.		1804 920* 1804 920* Requesting publication of SIR prior to Examiner action	
FEE CALCULATION		1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE		1251 110 2251 55 Extension for reply within first month	
Large Entity Small Entity		1252 420 2252 210 Extension for reply within second month 420.00	
Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee Paid		1253 950 2253 475 Extension for reply within third month	
1001 770 2001 385 Utility filing fee		1254 1,480 2254 740 Extension for reply within fourth month	
1002 340 2002 170 Design filing fee		1255 2,010 2255 1,005 Extension for reply within fifth month	
1003 530 2003 265 Plant filing fee		1401 320 2401 160 Notice of Appeal	
1004 770 2004 385 Reissue filing fee		1402 320 2402 160 Filing a brief in support of an appeal	
1005 160 2005 80 Provisional filing fee		1403 280 2403 140 Request for oral hearing	
SUBTOTAL (1) (\$)		1451 1,510 1451 1,510 Petition to institute a public use proceeding	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1452 110 2452 55 Petition to revive - unavoidable	
Total Claims -20** = Extra Claims Fee from below Fee Paid		1453 1,300 2453 650 Petition to revive - unintentional	
Independent Claims -3** =		1501 1,300 2501 650 Utility issue fee (or reissue)	
Multiple Dependent 290.00 =		1502 470 2502 235 Design issue fee	
Large Entity Small Entity		1503 630 2503 315 Plant issue fee	
Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee Paid		1460 130 1460 130 Petitions to the Commissioner	
1202 18 2202 9 Claims in excess of 20		1807 50 1807 50 Processing fee under 37 CFR 1.17(q)	
1201 86 2201 43 Independent claims in excess of 3		1806 180 1806 180 Submission of Information Disclosure Stmt	
1203 290 2203 145 Multiple dependent claim, if not paid		8021 40 8021 40 Recording each patent assignment per property (times number of properties)	
1204 86 2204 43 ** Reissue independent claims over original patent		1809 750 2809 375 Filing a submission after final rejection (37 CFR 1.129(a))	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent		1810 750 2810 375 For each additional invention to be examined (37CFR 1.129(b))	
SUBTOTAL (2) (\$)		1801 750 2801 375 Request for Continued Examination (RCE)	
**or number previously paid, if greater; For Reissues, see above		1802 900 1802 900 Request for expedited examination of a design application	
		Other fee (specify)	
		*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 550.00	
SUBMITTED BY		Complete (if applicable)	
Name (Print/Type) Nandakumar Govindaswamy		Registration No. (Attorney/Agent) Ltd. Recognition Telephone (617) 444-6619	
Signature		Date August 11, 2004	



VPI/02-143 US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael Allen Whitney, et al.
Serial No.: 10/656,029
Filing Date: September 5, 2003
Group Art Unit: 1636
Examiner: Not Yet Assigned
Confirmation No.: 8813
For: METHODS AND COMPOSITIONS FOR RAPID
DEVELOPMENT OF SCREENING ASSAYS

Cambridge, Massachusetts
August 11, 2004

MAIL STOP MISSING PARTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR RESPONSE TO THE
NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Sir:

Transmitted herewith in response to the Notice to File Missing Parts of
Nonprovisional Application – Filing Date Granted, mailed April 15, 2004 in the above-
identified application, are the following:

1. Faxcover Sheet to the Patent Office (1 page)
2. Fee Transmittal for FY 2004 (1 page, in duplicate);
3. Notice to File Missing Parts of Nonprovisional Application (2 pages); and
4. Executed Declaration document (9 pages).

Atty. Docket No.: VPI/02-143 US2
U.S.S.N.: 10/656,029
Applicants: Whitney, et al.

-2-

Applicants hereby authorize the Commissioner to charge Deposit Account No. 50-0725 in the amount of \$130.00 to cover the filing fee and the surcharge (see 37 C.F.R. §1.27 and 37 C.F.R. §1.16(e)).

Applicants believe that no additional fees are due at this time. However, the Commissioner is hereby authorized to charge payment of any additional fees required under 37 C.F.R. §1.16 in connection with the papers transmitted herewith, or credit any overpayment of the same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Nandakumar Govindaswamy, Ltd. Recognition
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6619
Fax.: (617) 444-6483



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Michael Allen Whitney, et al.
SERIAL NUMBER: 10/656,029 EXAMINER: Not Yet Assigned
FILING DATE: September 5, 2003 ART UNIT: 1636
CONFIRMATION NUMBER: 8813
FOR: METHODS AND COMPOSITIONS FOR RAPID DEVELOPMENT OF SCREENING ASSAYS

August 11, 2004
Cambridge, Massachusetts

MAIL STOP MISSING PARTS

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

**SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE
COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

1. ☒ This paper is in response to the Patent Office letter dated April 15, 2004.

☒ A copy of the Patent Office letter is enclosed.

Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.

☐ This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.

2. Submitted herewith are:

☐ A Preliminary Amendment directing entry of the Sequence Listing into the specification;

☒ a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and

☒ a copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS: Whitney, et al.
U.S.S.N.: 10/656,029


3. Statement:

I hereby state that: *(complete applicable items – A, B and/or C)*

- A. ☒ The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. ☐ The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. ☒ This submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0725, Ref. No. VPI/02-143 US2.

Respectfully submitted,



Nandakumar Govindaswamy, Ltd. Recognition
Attorney(s) for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6619
Fax: (617) 444-6483

Dated: August 11, 2004




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Nandakumar Govindaswamy is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Vertex Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein the patent application is assigned to Vertex Pharmaceuticals, Inc., and the attorney or agent of record in the applications is a registered practitioner who is an employee of Vertex Pharmaceuticals, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Nandakumar Govindaswamy ceases to lawfully reside in the United States, (ii) Nandakumar Govindaswamy's employment with Vertex Pharmaceuticals, Inc. ceases or is terminated, or (iii) Nandakumar Govindaswamy's current Employment Authorization card expires.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 1, 2004



Harry Moatz,
Director of Enrollment and Discipline